Transthera wins NMPA nod for post-FGFR cholangiocarcinomaTransthera Sciences Inc. has won Chinese approval for Yochanra (tinengotinib) in FGFR2-positive cholangiocarcinoma that has progressed after FGFR inhibitor therapy, potentially creating a new option for patients who have exhausted the targeted treatments that reshaped care for the molecularly defined cancer.